This is important because virtually all heart disease starts with accumulating arterial plaques or deposits inside the arteries' walls
Usage and visibility of GLP-1s have been increasing, especially among younger generations
These combinations help address multiple pathways at once
Micha, R., Wallace, S.K
The GLP-1 Receptor Agonist Cardiovascular Therapy market was dominated by North America region in 2025 fueled by the region's high rates of obesity, diabetes, and cardiovascular disorders
Commonly reported side effects include: Nausea, vomiting, or stomach cramps Diarrhoea or loose stools A distinctive 'fishy' body odour, caused by the production of trimethylamine a metabolic by-product of carnitine breakdown in the gut These gastrointestinal effects are more likely at higher doses, particularly above 3,000 mg per day, and are consistent with adverse effects described in the levocarnitine SmPC